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The book is divided in four parts. The first 
part is an Introduction to Cognitive Screen-
ing Instruments and Assessment of  the Util-
ity of  Cognitive Screening Instruments. The 
second part includes chapters that talk about 
patients’ performance-related test, the third 
one discusses informant-related scales, and 
the fourth one is the conclusion.
The first part discusses rationale and de-
siderata for effective cognitive screening in-
struments. In addition there is mention of  a 
potential risk such as age, education and cul-
ture on test performance and interpretations. 
Nowadays when in dementia diagnosis we 
use sophisticated neuroimaging techniques 
and biochemical tests, the role of  cognitive 
testing is being investigated. It is interesting 
that some authors consider that cognitive 
tests can be useful in predicting the conver-
sion and decline of  patients with moderate 
cognitive damage at risk of  progressing de-
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mentia as well as in neuroimaging and CFS 
tests. The significance of  appropriate appli-
cation and interpretation of  cognitive screen-
ing instruments in the early diagnostics of  
disorders is being stressed. Furthermore, 
there is an overview of  how tests’ accuracy 
study methods have been applied to cognitive 
assessment instruments, and authors stress 
the importance of  this research field. The 
numbers of  systematic reviews of  cognitive 
screening tests increases, as well as the num-
ber of  available cognitive tests, and authors 
encourage the research of  accuracy of  tests 
for dementia.
The second part brings a detailed over-
view of  certain cognitive tools in the assess-
ment of  a variety of  cognitive disorders. The 
first one is Mini Mental State Examination 
(MMSE) which is the most often used instru-
ment for cognitive damage. There is mention 
of  the latest evidence concerning the appli-
cation of  MMSE as a diagnostic test for de-
mentia, Mild Cognitive Impairment (MCI) 
and delirium. Numerous limitations of  this 
instrument are presented, and it is considered 
that it can only be used as the first step in 
screening dementia, MCI and delirium. Fur-
thermore, MMSE variants are described, the 
longer one which covers a broader horizon 
of  cognitive functions and the shorter one in 
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relation to the original as well as MMSE ad-
aptation for those with hearing or visual im-
pairment, for telephone use, for specific cog-
nitive problems with Parkinson’s disease etc.
Next presented instrument is Clock Draw-
ing test (CDT), very popular both in research 
and in clinical field. CDT psychometric prop-
erties are explored when used for cognitive 
screening in a variety of  neurologic condi-
tions, including Alzheimer’s disease, Parkin-
son’s disease, Hungtington’s disease, vascular 
disease, schizophrenia, stroke, and traumatic 
brain injury. In addition, Addenbrooke’s Cog-
nitive Examination is demonstrated, which 
is assessed by systematic reviews as capable 
of  differentiating patients with or without 
cognitive damage and with the existing evi-
dence for detecting dementia and lesser cog-
nitive damage in conditions such as AD,MCI, 
stroke, brain injury, etc. The following in-
strument is Montreal Cognitive Assessment 
(MoCA), cognitive screening, developed for 
detecting mild cognitive impairment (MCI). 
It is a simple paper and pencil test, lasts for 
10 minutes and assesses multiple cognitive 
domains including memory, executive func-
tion, language, calculation, visuospatial skills, 
abstraction, attention, concentration, and 
orientation. Furthermore, there is DemTect, 
cognitive screening instrument, sensitive to 
the early cognitive symptoms of  dementia, 
recommended only to be used as the first 
step in assessment, and Test Your Memory 
(TYM) test, new short cognitive test for the 
detection of  Alzheimer’s disease and other 
cognitive problems, and it is considered to 
have clear advantages over more established 
tests in some clinical fields. Next one is Gen-
eral Practitioner Assessment of  Cognition 
(GPCOG), very brief  cognitive test for use 
in primary care, Six-item Cognitive Impair-
ment Test (6CIT), designed to assess global 
cognitive status in dementia and Quick Mild 
Cognitive Impairment screen (Qmci), test 
for differentiating patients with mild cogni-
tive impairment from those with subjective 
memory complaints and dementia.
Third part explores Informant-Related 
Scales. The first one is Informant Question-
naire on Cognitive Decline in the Eldery 
(IQCODE) which uses the report of  an in-
formant to assess changes in cognition in 
the last 10 years. The main limitation is that 
it can be affected by informant’s emotional 
state, although it is a suitable screening test 
in clinical settings, for retrospective cognitive 
assessment where direct data are not avail-
able, and for assessment in large scales epi-
demiological studies. This scale is followed 
by Brief  Informant Interviews to Screen for 
Dementia: AD8 and Quick Dementia Rat-
ing System. The AD8 is an informant-based 
dementia screening test designed to capture 
intra-individual change in cognitive and func-
tional abilities. It lasts 2-3 minutes, and it is 
in high correlation with Clinical Dementia 
Rating Scale, neuropsychological testing, ce-
rebrospinal fluid and imaging biomarkers of  
Alzheimer’s disease. The Quick Dementia 
Rating System is a ten-item multiple choice 
questionnaire that takes 3-5 minutes and pro-
vides a quantitative assessment of  cognitive, 
functional, and behavioral domains to stage 
dementia severity.   
The last one, fourth part, is a conclusion. 
It sums up the fact that cognitive screening 
instruments remain an integral part of  the as-
sessment of  any patient with cognitive com-
plaints. 
This book is of  great importance for ex-
perts dealing with mental health (psychia-
trists, psychologists, neurologists, general 
practitioners...) and the fact that the first edi-
tion, in the period from 2013 till the end of  
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2015, achieved nearly 18000 chapter down-
loads speaks for itself. Instruments are pre-
sented in detail and are accompanied with 
research overviews with clear indication of  
both advantages and limitations. This last 
edition, enriched with new chapters, will for 
sure be as successful as the previous one. 
Anamarija Bogović, PhD
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Delirium is an acute, transient, usually 
changeable and reversible state of  distur-
bance of  attention, cognition and degree of  
consciousness. It can be caused by almost any 
disorder, intoxication or drug use.  Delirium 
can arise at any age but is more common in 
older people.
In the first part of  the book, the psycho-
pathology of  the disease is described briefly 
followed by the part in which clinical fea-
tures are explained. Authors described neu-
rotransmitters associated with delirium like 
acetylcholine, dopamine, serotonin, gamma 
aminobutryic acid, glutamate, and also con-
nection of  inflammatory response and de-
lirium where cytokines have the main role. 
Other pathogenesis of  delirium like corti-
sol, genetic, drug, changes in neural injury 
and permeability of  blood brain barrier, and 
impairment in sleep pattern are mentioned. 
Due to various signs and symptoms of  de-
lirium it may not be recognized in elderly pa-
tients and might be misinterpreted as some 
other mental disorders such as dementia, de-
pression or natural course of  ageing. Three 
clinical subtypes of  delirium are described; 
hyperactive delirium, hypoactive delirium and 
mixed forms. Diagnosis of  delirium is based 
on detailed history, behavioral observation 
and cognitive assessment and requires mul-
tidisciplinary vigilance and a low threshold 
for diagnosis. In the book, apart from clin-
ical features, DSM V or ICD-10 diagnostic 
criteria are described. Since delirium can be 
confused with several psychiatric disorders, 
it is important to distinguish delirium from 
dementia, depression, and other disorders, 
therefore the authors described it in separate 
chapters.
The last part of  book describes different 
approaches to elderly patients with delirium; 
from geriatrician’s to neurologist’s perspec-
tive, intensive care specialist’s perspective and 
nursing perspective and delirium prevention. 
At the end of  the book, a few case reports 
have been described, which has come as an 
excellent summary in relation to the forego-
ing.
This book provides a comprehensive, 
scholarly, and practical account of  delirium 
and it is interested and useful for profession-
als working in geriatrics, psychiatry, neurol-
ogy, internists, and intensive care units.
Mirna Peco, MD
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This book covers important and growing 
field of  knowledge associated with the role 
of  inflammation in depression. This essential 
guide is edited and written by eminent inter-
national experts Robert Danzer and Lucile 
Capuron. Robert Danzer is the pioneer in the 
field of  such research, establishing the con-
cept of  “sickens behaviour” that was the fun-
dament of  the research in immunology and 
depression following. Both editors have de-
cades of  experience in the research of  associ-
ations between inflammation and depression. 
The authors of  the chapters are also world 
leading experts in the field. 
The book covers the development of  the 
idea that behaviour in sickness might have 
implications on emotions and covers over 20 
year’s long path of  intrusion of  inflammation 
in the field of  depression. The book also ex-
amines possible usefulness of  pharmacologi-
cal and non pharmacological interventions 
targeting various inflammatory processes. 
The book consists of  three parts: evi-
dence for inflammation associated depres-
sion, mechanism of  inflammation associated 
depression and clinical implications of  the 
current knowledge in role of  inflammation 
in depression. 
The first part explores current preclinical 
and clinical evidence that support the rela-
tionship between inflammation and depres-
sion.
The second part presents our current 
knowledge of  the mechanism of  action of  
inflammatory mediators on brain functions 
and what is known of  immune to brain com-
munication pathways and haw it has been 
shown on animal models.
The third part consists of  the review of  
current and promising agents in the depres-
sion treatment like anti-inflammatory drugs, 
polyunsaturated fatty acids and non-steroidal 
anti-inflammatory drugs. Also the novel pos-
sibilities for treatment are critically reviewed.
The book is well written and presented 
with many diagrams and illustrations.
It covers the gap in this area of  psychia-
try research and potential for clinical practice 
and will be of  interest for clinicians and re-
searchers worldwide.
Branka Aukst Margetic, MD,PhD
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This excellent book examines the psycho-
social impacts of  cancer and its management, 
explaining the relevance of  psycho-oncology 
during all stages from diagnosis and treat-
ment through to cancer survivorship and 
rehabilitation and end-of-life care. Editors 
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Ute Goerling and Anja Mehnert are leading 
experts in this field and guarantee that this 
book will be a valuable read.
The book is divided in 14 chapters. Chap-
ter 1 is focused on psychosocial impact of  
cancer and explains how diagnosis and treat-
ment of  malignant diseases in many ways af-
fect the lives of  patients, relatives and friends. 
Chapter 2 is focused on fear of  progression 
in cancer patients and survivors which is one 
of  most frequent distress symptoms of  pa-
tients with cancer. Chapter 3 describes gen-
der opportunities in psychosocial-oncology 
where sex and gender are put into a historical 
context that is relevant to psycho-oncology. 
Chapter 4 discusses a patient’s view in psy-
cho-oncology, when Chapter 5 is focused on 
the oncological patient in the palliative situ-
ation. Chapter 6 explains the consequences 
of  caring in the context of  family caregivers, 
while Chapter 7 gives us insight in rehabili-
tation for cancer patients. Chapters 8, 9 and 
10 talk about cancer survivorship in adults, 
psychotherapy in the oncology setting and 
quality of  life in oncology. In the last four 
chapters we can read about psychosocial im-
pact of  personalized therapies in oncology; 
COMSKIL Communication training in On-
cology program; the barrier of  informed 
choice in cancer screening and future re-
search in psycho-oncology.
This book is a remarkable work that con-
tains all the relevant knowledge in this com-
plex field and will indeed serve as a valuable 
resource for all health care professionals who 
work with patients and their relatives in the 
field of  psychosocial cancer care and oncolo-
gy. I feel the need to congratulate the authors 
for an exquisite work.
Darko Vlahović, MD
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Via XIII Sections, in concise but quite in-
formative manner, a medical approach to psy-
chotropic prescribing is presented. Following 
the initial (I) Section, with the introduction 
on general principles of  prescribing psycho-
tropic medication in people with preexisting 
medical conditions, twelve sections address 
various medical systems disorders / altera-
tions, accompanied with psychotropic agents 
prescription. Section two (II) analyses signifi-
cant components of  metabolic syndrome: 
obesity, glycemia-related abnormalities, blood 
pressure (BP)-related abnormalities and hy-
perlipidemia. Obesity, a common side effect 
of  various antipsychotics, antidepressants 
and mood stabilizers, the underlying mech-
anisms contributing to appetite increase, as 
well as suggested intervention guidelines are 
discussed within Section II. Glycemia-related 
abnormalities (such as diabetes mellitus and 
acute hyperglycemia), increased BP (in form 
of  hypertension or acute hypertensive cri-
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sis) and lipid levels alterations are conditions 
frequently found not only in patients using 
various psychopharmaceutics but also in pa-
tients on different non-CNS targeting agents. 
In a couple of  chapters in Section II, a spe-
cial attention is given to the antipsychotics, 
antidepressants and mood stabilizers which 
could be associated with significant glycemia-
related abnormalities, BP level abnormalities 
and/or dys/hyperlypidemia. Preventive and 
intervention procedures, including medica-
tion switch and structured lifestyle interven-
tions implementation, as well as prescribing 
metformin for slowing or stopping conver-
sion of  pre-diabetes to diabetes, and instruc-
tions for appropriate acute hyperglycemia 
management, are suggested for glycemia-
related abnormalities. Usually psychotropic 
medications cause a small elevation of  BP, 
but when a psychopharmaceutical agent con-
tributes to BP rise >10 mm Hg or is consid-
ered to be the primary or significantly con-
tributing cause of  de-novo developed and 
diagnosed arterial hypertension with the con-
secutive need for antihypertensive therapy, 
drug switch should be considered. For dys-
lipidemia, as well as for the other conditions 
that are part of  metabolic syndrome, preven-
tion is the best treatment. When that route to 
maintaining healthy metabolism is not pos-
sible, prescribing strategies such as choosing 
psychopharmaceuticals with the lowest po-
tential for causing dyslipdemia and/or weight 
gain, lifestyle modification implementation 
and statin add-on in indicated cases should 
be applied. Cardiovascular system-related 
psychotropic side effects (such as orthostatic 
hypotension, tachicardia, QTc prolongation, 
non Q-T conduction abnormalities and pe-
ripheral edema), endocrine system-related 
abnormalities (such as hyperprolactinemia, 
hypo- and hyperthyroidism) and kidney- and 
electrolyte-related psychotropic side effects 
are in straightforward but at the same time 
clinically precise manner elaborated in Sec-
tions III-V. Sexual dysfunction, urinary in-
continence and retention, as the most fre-
quent urinary system-related psychotropic 
side effects are elaborated in two chapters 
of  Section VI. Practical guidelines are given 
regarding successful solving of  these distur-
bances/side effects. Some of  the most com-
mon drug-induced gastrointestinal system-
related side effects (such as constipation, 
particularly associated with some antipsy-
chotics use) and hematologic system related 
side effects (such as leukopenia, neutropenia 
or thrombocytopenia), their adequate recog-
nition, monitoring and successful solving are 
discussed in Sections VII-VIII. Skin/cutane-
ous reactions, as common adverse effects of  
psychopharmaceutical agents, are in the fo-
cus of  Section IX. Most of  them are benign, 
but if  they are qualified as „serious“, the pre-
scribed pharmaceutical should be promptly 
stopped. Movement disorders are in straight-
forward manner elaborated in Section X. 
Neurologic conditions such as tremor, Par-
kinsonism, dystonia, akathisia and tardive 
dyskinesia are clinically significant and often 
seen in everyday practice. They are explored 
in detail, and their successful management is 
suggested. Separate section (Section XI) pays 
attention to syndromes such as serotonin syn-
drome and neuroleptic malignant syndrome. 
Practical and clinical guidelines for success-
ful management of  serious condition such as 
neuroleptic malignant syndrome are given in 
clear and simple but at the same time infor-
mative manner. Finally, the last two sections 
addressed some selected neurologic system-
related conditions not already discussed in 
previous sections, such as seizures (Section 
XII), and some other various systems-relat-
73
Alcoholism and Psychiatry Research 2018;54:67-74Book review
ed conditions not already covered in previ-
ous sections (such as sedation or xerostomia, 
Section XIII). Generally, one could conclude 
that the book is written in simple and concise 
but at the same time informative enough ap-
proach, so that readers get good educational 
material and coherently structured textbook 
which addresses various systems-related psy-
chotropic side effects.
Maja Vilibić, MD, PhD
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Last few decades witnessed an amazing 
increase of  neuroscience research, expanding 
our understanding and knowledge of  neu-
robiological processes underlying practically 
every psychiatric and neurologic entity. How-
ever, no other area of  research was as exhaus-
tive as dementia research. Some could argue 
that this is due to a modest starting point, 
compared to let’s say depression, addiction 
or schizophrenia, which have during the last 
couple of  centuries all been at some point a 
main focus of  psychiatric interest. Far from 
the fact that we learned everything we need 
to know in the previously mentioned areas, 
but the burden of  dementia has increased 
dramatically, leading to a growing number of  
affected individuals, enormous strain their 
families and communities are experiencing, 
and putting national budgets under consider-
able pressure due to growing health and so-
cial expenses. Therefore it is not a surprise 
that researchers identified dementia as a pri-
ority. Thankfully, that research is not solely 
academic, but slowly beginning to pay off. 
In the last decades we witnessed the birth 
of  first specific anti-dementia treatments, as 
well as identification and conceptualization 
of  other possible targets that are currently 
in development. We have also learned a great 
deal about human cognition and various neu-
rocognitive domains, which are so clearly af-
fected in dementias, and that knowledge is 
nowadays being used across the entire neuro-
psychiatric spectrum. We have also gained in-
valuable insight into genetic and biochemical 
processes underlying specific dementias, Al-
zheimer’s, Parkinson’s, Lewy body to name a 
few, which could provide us with the answers 
we seek while designing a more specific and 
effective therapy. Still, comprehensive text-
books focusing specifically on dementia have 
until now seldom been published, leaving a 
giant gap between the considerable amassed 
body of  knowledge regarding dementias and 
the need to implement that knowledge by 
mental health care professionals dealing with 
those affected with these illnesses. That does 
not mean that books dealing with the topic 
of  dementia have not been previously pub-
lished, but it does mean the impact of  those 
books, in terms of  utilizing evidence based 
medicine and improving healthcare and social 
outcomes, was rather low. To be fair, relatively 
widespread perception of  dementia as an un-
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treatable illness with a scarce therapeutic ar-
mamentarium did not help either. That being 
the case, resources like Dementia by Ames, 
O’Brien and Burns, give hope that someday 
we could alter treatment outcomes and de-
mentia prognosis. Before that time comes, we 
have to get intimately acquainted with all the 
different aspects of  dementia, and in that as-
pect this volume just shines. Spanning over 
900 pages, divided into almost 80 chapters, 
we can in one place find almost every impor-
tant piece of  information about dementias, 
from its general aspects to specific topics of  
rare types of  dementia. Considerable space 
has also been reserved for legal and ethical 
issues and various social aspects of  dementia, 
from the caregiver burden to social case man-
agement, and also specific issues which have 
often been neglected in terms of  dementia, 
such as driving and dementia or sexuality 
and dementia, to name but a few. Although 
a medical resource, authors clearly intended 
this book to surpass its medical formulation 
and attempted to sway the focus away from 
just the expected focal points, such as diag-
nostics, clinical presentation and treatment. 
By doing so, this resource opened to a far 
wider public, which reflects the essential need 
for an interdisciplinary and multimodal ap-
proach to dementias. I firmly believe authors 
succeeded at that task, as this volume can be 
used as a central resource for all social and 
health care professionals involved in manage-
ment of  those suffering from dementias.  
Assistant Prof. Vjekoslav Peitl, MD, PhD
